Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

LivaNova PLC (LIVN) SEC Filings & Earnings Calls

EquiReason read 10 LivaNova PLC SEC filings in the last 12 months. Latest: 10-Q on 2026-08-05 — LivaNova reported strong Q2 2026 results with revenue growth of 10.8% and net income of $108.6 million, benefiting from tariff refunds and a tax ruling..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

LIVNLivaNova PLCFollow LIVN — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
4.5B
P/E TTM
23.9
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

5 Aug 202610-QLivaNova reported strong Q2 2026 results with revenue growth of 10.8% and net income of $108.6 million, benefiting from tariff refunds and a tax ruling.earningsopen

Figures in the filing · each found in the filing text

Net revenue · Q2-2026$391M+11% y/y
Net revenue · H1-2026$753M+12% y/y
Net income (loss) · Q2-2026$109M+300% y/y
Net income (loss) · H1-2026$131M-144% y/y
Cardiopulmonary net revenue · Cardiopulmonary · Q2-2026$222M+11% y/y
Neuromodulation net revenue · Neuromodulation · Q2-2026$167M+10% y/y
Cardiopulmonary segment income · Cardiopulmonary · Q2-2026$28M-10% y/y
Neuromodulation segment income · Neuromodulation · Q2-2026$61M+9% y/y
Cost of sales as % of net revenue · Q2-202629.9%
SG&A as % of net revenue · Q2-202640.5%

Risks flagged

Litigation liability from 3T Heater-Cooler device

“Other operating expense as a percentage of net revenue was 3.2% and 1.6% for the three and six months ended June 30, 2026, respectively, representing increases of 3.2 and 1.5 percentage points compared to the three and six months ended June 30, 2025, respectively, primarily due to increases of $11.4 million and $10.7 million in the amount recorded for the li”

SNIA environmental liability

“As a result of the decision by the Italian Supreme Court, the Company recorded €333.3 million ($362.1 million) as SNIA environmental liability expense for the six months ended June 30, 2025.” · word for word

Foreign exchange volatility

“Foreign exchange and other income/(expense) was expense of $23.8 million and $29.5 million for the three and six months ended June 30, 2026, respectively, compared to expense of $4.3 million and income of $7.2 million for the three and six months ended June 30, 2025, respectively.” · word for word

Valuation allowance on deferred tax assets

“Depending on operating results in the future, a release of a valuation allowance could occur within the next 12 months.” · word for word
Read the original on SEC EDGAR ↗
5 Aug 20268-K · 2.02LivaNova reports Q2 2026 revenue of $390.6M (+10.8% reported, +9.8% constant currency), raises FY2026 revenue growth guidance to 8-9% from 7-8% and adjusted EPS to $4.30-$4.40 from $4.20-$4.30. Also announces long-term supply agreement withearningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$391M+11% y/y
Adjusted diluted EPS · Q2-2026$1.26+20% y/y
GAAP diluted EPS · Q2-2026$1.93+286% y/y
Adjusted operating income · Q2-2026$91M+17% y/y
Net cash provided by operating activities · Q2-2026$67M
Adjusted free cash flow · Q2-2026$46M
Cardiopulmonary revenue · Cardiopulmonary · Q2-2026$222M+11% y/y
Neuromodulation revenue · Neuromodulation · Q2-2026$167M+10% y/y

Guidance

FY2026 revenue growth raised to 8-9% from 7-8% on constant-currency basis; FY2026 adjusted diluted EPS raised to $4.30-$4.40 from $4.20-$4.30; FY2026 adjusted free cash flow lowered to $140-160M

Raised full-year revenue and EPS guidance reflecting strong execution and demand

Risks flagged

Supply chain dependency on single oxygenator component supplier

“Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply” · word for word

Lowered adjusted free cash flow guidance for FY2026

“Lowered full-year 2026 adjusted free cash flow range to $140 million to $160 million” · word for word
Read the original on SEC EDGAR ↗
6 May 20268-K · 2.02Revenue $362M (+14% y/y); Cardiopulmonary Revenue $209M (+18% y/y); Neuromodulation Revenue $152M (+9% y/y); Guidance: Revenue growth guidance raised by 100 bps to 7-8% constant-currency; adjusted diluted EPS raised by $0.05 to $4.20-$4.30earningsopen

Figures in the filing · each found in the filing text

Revenue · Total · Q1-2026$362M+14% y/y
Cardiopulmonary Revenue · Cardiopulmonary · Q1-2026$209M+18% y/y
Neuromodulation Revenue · Neuromodulation · Q1-2026$152M+9% y/y
GAAP Diluted EPS · Q1-2026$0.40
Adjusted Diluted EPS · Q1-2026$0.98+11% y/y
Net Cash Provided by Operating Activities · Q1-2026$15M
Adjusted Free Cash Flow · Q1-2026$4M

Guidance

Revenue growth guidance raised by 100 bps to 7-8% constant-currency; adjusted diluted EPS raised by $0.05 to $4.20-$4.30

Raised full-year guidance on strong Q1 performance and positive outlook.

Risks flagged

Foreign currency exposure may impact reported results.

“Constant-currency adjustments indicate FX impact; guidance provided on constant-currency basis.”
Read the original on SEC EDGAR ↗
6 May 202610-QNet revenue $362M (+14% y/y); Cardiopulmonary net revenue $209M (+18% y/y); Neuromodulation net revenue $152M (+9% y/y)open

Figures in the filing · each found in the filing text

Net revenue · Q1-2026$362M+14% y/y
Cardiopulmonary net revenue · Cardiopulmonary · Q1-2026$209M+18% y/y
Neuromodulation net revenue · Neuromodulation · Q1-2026$152M+9% y/y
Gross profit · Q1-2026$244M+13% y/y
Net income · Q1-2026$22M
Operating income · Q1-2026$41M-15% y/y
R&D expense · Q1-2026$59M+55% y/y
SG&A expense · Q1-2026$144M+11% y/y
Cardiopulmonary segment income · Cardiopulmonary · Q1-2026$30M+22% y/y
Neuromodulation segment income · Neuromodulation · Q1-2026$44M-16% y/y

Risks flagged

SNIA environmental liability

“The Italian Supreme Court determined that LivaNova can be held jointly and severally liable for the established liabilities of SNIA... the Company recorded €333.3 million ($360.4 million) as SNIA environmental liability expense for the three months ended March 31, 2025.” · word for word

Gross margin pressure from product mix

“Cost of sales as a percentage of net revenue was 32.7% for the three months ended March 31, 2026, representing an increase of 1.0 percentage points compared to the three months ended March 31, 2025, primarily due to unfavorable product mix.” · word for word

Contingent consideration volatility

“$9.7 million of higher expense from the net unfavorable change in fair value of contingent consideration arrangements associated with the ImThera acquisition” · word for word
Read the original on SEC EDGAR ↗
29 Apr 2026DEF 14ALivaNova filed its DEF 14A proxy statement for the 2026 Annual General Meeting, detailing executive compensation, corporate governance, and shareholder proposals.open

Figures in the filing · each found in the filing text

Revenue · FY2025$1.39B+11% y/y
Operating Income (GAAP) · FY2025$199M+55% y/y
Adjusted Operating Income · FY2025$286M+20% y/y
Net Cash Provided by Operating Activities · FY2025$254M
Adjusted Free Cash Flow · FY2025$183M
Net Income · FY2025$-243M
Total Shareholder Return (TSR) · FY2025$92.93
Peer Group TSR · FY2025$126.87
Employees · FY20253,300
Net Sales (STIP Target) · FY2025$1.32B

Risks flagged

Supply Chain Constraints

“Partially achieved primarily due to external supply constraints and the impact of market-related factors, despite solid pricing performance.” · word for word

Cybersecurity Risk

“Notwithstanding the Company’s approach to cybersecurity, LivaNova may not be successful in preventing or mitigating future cybersecurity incidents that could have a material adverse effect on the Company.” · word for word

Regulatory and Reimbursement Risk

“In June 2025, the Company initiated the process with the U.S. Centers for Medicare & Medicaid Services (“CMS”) to seek reconsideration of national Medicare coverage for VNS Therapy™ in unipolar treatment-resistant depression” · word for word
Read the original on SEC EDGAR ↗
25 Feb 20268-K · 2.02Total Revenue $361M (+12% y/y); Full Year Revenue $1.39B (+11% y/y); Adjusted Diluted EPS $0.86; Guidance: FY2026 constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25earningsopen

Figures in the filing · each found in the filing text

Total Revenue · Q4-2025$361M+12% y/y
Full Year Revenue · FY2025$1.39B+11% y/y
Adjusted Diluted EPS · Q4-2025$0.86
Full Year Adjusted Diluted EPS · FY2025$3.90
Cardiopulmonary Revenue · Cardiopulmonary · Q4-2025$207M+14% y/y
Neuromodulation Revenue · Neuromodulation · Q4-2025$153M+11% y/y
Adjusted Free Cash Flow · FY2025$183M

Guidance

FY2026 constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25

FY2026 guidance reflects continued growth and margin expansion; aligned with medium-term outlook from Investor Day.

Risks flagged

SNIA environmental liability expense of $365.6M impacted GAAP results; non-recurring but significant.

“Full-year 2025 U.S. GAAP diluted loss per share of $4.45, impacted by recording the SNIA environmental liability expense of $365.6 million” · word for word
Read the original on SEC EDGAR ↗
25 Feb 202610-KRisks named: Tariff and Trade Policy Risk, Supply Chain Disruption Risk, Cybersecurity Incident Risk, Product Liability Litigation Riskopen

Risks flagged

Tariff and Trade Policy Risk

“A significant number of LivaNova's Cardiopulmonary products and component parts are sourced and produced outside of the U.S., including in Italy and Germany.” · word for word

Supply Chain Disruption Risk

“supplier shortages and interruptions of certain components, such as the fiber used in the manufacture of oxygenators and rare earth magnets used in the manufacture of heart-lung machines, have caused, and may in the future cause, meaningful disruptions to LivaNova's product manufacturing supply chain.” · word for word

Cybersecurity Incident Risk

“The Company has experienced and is continually at risk of being subject to cybersecurity incidents and other disruptions, as exemplified by the previously disclosed November 2023 cybersecurity incident that resulted in the disruption of portions of the Company's IT systems.” · word for word

Product Liability Litigation Risk

“the Company is involved in product liability litigation relating to its cardiopulmonary 3T Heater-Cooler product that has adversely affected LivaNova's financial condition and has required the Company to devote significant resources to its defense and/or settlement of these claims.” · word for word
Read the original on SEC EDGAR ↗
14 Jan 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Key legal officer departure creates temporary leadership gap and potential operational disruption.

“Resignation effective within two weeks; external search initiated.”
Read the original on SEC EDGAR ↗
5 Nov 20258-K · 2.02Revenue $358M (+12% y/y); GAAP diluted EPS $0.49 (-18% y/y); Adjusted diluted EPS $1.11 (+23% y/y); Guidance: Revenue growth raised to 8.5%-9.5% constant-currency (from 8.0%-9.0%); adjusted EPS to $3.80-$3.90 (from $3.70-$3.80); adjusted FCearningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$358M+13% y/y
GAAP diluted EPS · Q3-2025$0.49-18% y/y
Adjusted diluted EPS · Q3-2025$1.11+23% y/y
Net cash from operating activities · Q3-2025$85M
Adjusted free cash flow · Q3-2025$62M
Cardiopulmonary revenue · Cardiopulmonary · Q3-2025$203M+18% y/y
Neuromodulation revenue · Neuromodulation · Q3-2025$150M+7% y/y

Guidance

Revenue growth raised to 8.5%-9.5% constant-currency (from 8.0%-9.0%); adjusted EPS to $3.80-$3.90 (from $3.70-$3.80); adjusted FCF to $160M-$180M (from $140M-$160M)

Raised guidance across revenue, EPS, and FCF; management tone confident.

Risks flagged

Foreign currency fluctuations could impact results.

“Foreign currency is expected to be a tailwind of approximately 1.0% based on current exchange rates.” · word for word
Read the original on SEC EDGAR ↗
5 Nov 202510-QLivaNova reported Q3 2025 results with strong revenue growth in both segments, but a significant SNIA environmental liability charge impacted net income.earningsopen

Figures in the filing · each found in the filing text

Net revenue · Q3-2025$358M+13% y/y
Net income · Q3-2025$27M-19% y/y
Cardiopulmonary revenue · Cardiopulmonary · Q3-2025$203M+18% y/y
Neuromodulation revenue · Neuromodulation · Q3-2025$150M+7% y/y
Cardiopulmonary segment income · Cardiopulmonary · Q3-2025$25M+14% y/y
Neuromodulation segment income · Neuromodulation · Q3-2025$56M+13% y/y

Risks flagged

SNIA environmental liability

“The Italian Supreme Court determined that LivaNova can be held jointly and severally liable for the established liabilities of SNIA ... the Company recorded the SNIA environmental liability expense in the quarter ended March 31, 2025” · word for word

Cybersecurity incident costs

“Through September 30, 2025, LivaNova incurred direct costs totaling $13.1 million in connection with this cybersecurity incident” · word for word
Read the original on SEC EDGAR ↗

LivaNova PLC — questions

What did LivaNova PLC file recently?
10 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-05 — LivaNova reported strong Q2 2026 results with revenue growth of 10.8% and net income of $108.6 million, benefiting from tariff refunds and a tax ruling.

Every figure on this page comes from LivaNova PLC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.